If you’re looking for a Cardiology CRO, you’ve come to the right place. Vial CRO offers advanced science, strong relationships with sites, and responsiveness and operational rigor to help clients realize their development goals. In this article, we’ll provide you with an overview of the different types of Cardiology CRO available and discuss which ones might be best for your needs.
Vial CRO
Vial CRO is a specialty-focused Cardiology CRO that delivers the complete spectrum of clinical research services for the cardiovascular industry. With expertise in advanced science and an agile, collaborative approach, Vial CRO can help you achieve your development goals. The company’s team of experts, strong relationship with study sites, and operational rigor make it an ideal partner for cardiovascular clinical trials.
CROs can conduct trials with a global focus. They can scale up large trials and can manage multiple trials at once. They can also apply agile trial management practices to meet the diverse needs of global clinical trials. Despite the high costs associated with large trials, CROs are able to manage these studies effectively and rapidly.
Academic research organizations have played a pivotal role in the development of modern cardiovascular trials. While contract research organizations are generally for-profit corporations, they are generally affiliated with universities and other higher learning institutions. In the early years of clinical trials, academic medical centers often collaborated with pharmaceutical companies and regulatory bodies to perform studies.
ICON
ICON is a full-service cardiovascular CRO with years of experience conducting clinical trials. Cardiovascular diseases are the leading causes of morbidity and mortality worldwide. The firm focuses on key cardiovascular/metabolic indications and takes a data-driven approach to developing its strategies. ICON has the expertise and experience to successfully manage clinical trials for cardiovascular and metabolic disorders.
Also, The firm has offices in 76 locations across 37 countries and has more than 10300 employees. Its services span the life sciences industry, from biotechnology to pharmaceuticals. ICON also offers services in biosimilars, diagnostics, and patient access tools. As the world’s largest Cardiology CRO, Icon has the capability to deliver high-quality clinical research across a variety of therapeutic areas.
Cardialysis
Cardialysis is also an independent Cardiology CRO with more than 30 years of experience. It has a consolidated monitoring network that spans Europe and is staffed with clinical research associates who have more than five years of experience in coordinating trials. Its centralized monitoring network allows it to monitor clinical trials in multiple countries and ensure high-quality data collection and analysis. In addition, Cardialysis has expertise in web-based clinical event adjudication and data management, which makes it an ideal partner for a cardiac study.
Cardialysis is a leading cardiovascular research organization and offers a comprehensive range of services to pharmaceutical and device manufacturers. Its services include full protocol development, data management and reporting. Also, It has a network of over 1400 clinical sites and access to a vast pool of prospective trial participants. Cardialysis also has a proven track record of executing successful clinical trials. Its services have helped to advance cardiac care in many countries around the world, leading to the approval of new drugs and devices.
CROMSOURCE
CROMSOURCE is an ISO-certified global contract research organization (CRO) with expertise in clinical development and flexible resourcing solutions. Founded in 1997, the company has experienced consistent growth and development, with a reputation for stability, integrity, and high customer satisfaction. It has offices in all regions of Europe and North America, and has an extensive portfolio of clinical research services.
CROMSOURCE has over 20 years of experience leading teams in complex clinical research. Its management team includes senior executives who have extensive experience at every level of the company. The management team at CROMSOURCE is led by Dr. Ross, who brings extensive expertise in operations, commercial strategy, and patient care. She joined the company in 2005, and has since held key positions in the company’s commercial and operational functions. She previously served as well as Head of EU Operations at Catalyst Pharma Group, where she was responsible for all of the company’s corporate development activities.
CROMSOURCE has a strong track record in clinical research projects, with extensive experience in cardiovascular disease research. Its clinical teams have conducted a wide range of studies, including large pivotal international trials and registry studies that collect large datasets. They are also experienced in medical device studies, including cardiac valves, drug-eluding stents, catheters, and vascular imaging media.
Read also: Oncology CRO Services
ICON Global Monitoring Network
ICON is a leading global Cardiology CRO. Founded in 1990, the company employs over 15,000 clinical research professionals in 94 locations across 40 countries. It offers a range of services ranging from clinical development to commercialization, with a particular focus on cardiovascular medicine. In addition to clinical trials, ICON provides consulting and regulatory support for companies wishing to conduct clinical research.
Cardialysis in Europe
The research and development activities of Cardialysis span the entire continent. With a strong academic background and a long track record in cardiovascular research, Cardialysis plays an important role in the development of new treatments. In addition, the organization facilitates the design of multi-center clinical trials. It acts as well as a trial sponsor and collaborates with renowned research organizations worldwide.
The organisation’s staff is highly qualified to handle trials, including per-study visits to ensure that participating sites meet Good Clinical Practice guidelines and trial-specific requirements. This ensures good site collaboration and the early detection of potential issues. The organization also provides general site management, including answering questions from sites, assisting with study-specific procedures, collecting signatures and performance counts, and notifying sites of follow-up visits and queries.
Sticares Inter ACT, a Netherlands-based CRO, has formed a strategic alliance with Cardialysis. Together, the companies have access to new technologies and advanced cardiovascular trial services.
ICON Global Monitoring Network in the US
Amgen will join the CardioHealth Alliance in late 2021, with the goal of reversing the burden of cardiovascular diseases. The alliance’s leadership includes Dr. Ponda Motsepe-Ditshego of Amgen Medical Affairs, Dr. Hernandez, and Dr. Mahaffey of CardioHealth Sciences. Together they shared their perspectives on the importance of collaboration across sectors and the power of partnerships.
With the growing prevalence of chronic heart disease, technology infrastructure improvements are essential for managing patients in out-of-hospital settings. Cardiology leaders see technology infrastructure upgrades as well as vital to managing a tsunami of new patients. A new study, conducted by Philips Future Health Index 2022, found that cardiology leaders prioritize telehealth and artificial intelligence. In fact, this priority is higher than the global average of all healthcare leaders.
Cardialysis in the Netherlands
Cardialysis and Sticares InterACT, two Contract Research Organizations based in The Netherlands, have announced a strategic collaboration to provide pharmaceutical companies with consulting services in cardiovascular and metabolic medicine. Both organizations have extensive experience in conducting clinical research projects. They also have complementary service offerings in the areas of cardiovascular and metabolic medicine.
Cardialysis is a leading cardiology-focused clinical research organization offering full clinical research and cardiac core laboratory services. Founded in 1983, Cardialysis has strong academic affiliation, an opinion leader network, and advanced core laboratory technologies. Since then, it has conducted more than 250 clinical trials and collaborated with several leading medical device and biotechnology companies.
Cardialysis’s specialized Structural Heart Core Lab, which has extensive experience in the analysis of transcatheter therapies, is a key partner for transcatheter therapy clinical trials. The lab has successfully analyzed thousands of imaging data from clinical trials.
Data has been used for FDA and CE mark submissions. European Cardiovascular Research Institute, or ECR Institute, provides a platform for investigator-initiated trials in Europe. Also as sponsor, the institute makes sure that all clinical trial procedures are compliant with ICH GCP guidelines. It is committed to the safety and quality of patient care.
Cardialysis in the US
Cardialysis is also one of the world’s leading providers of cardiovascular core laboratory and clinical research services. It has conducted over 400 clinical trials to improve the treatment of cardiovascular disease and improve patient outcomes. With an extensive global network and in-depth methodological expertise, Cardialysis is capable of managing large-scale trials of new drugs and devices.
Cardialysis collects and processes the personal data of customers, business partners, health care professionals, and suppliers. This personal data is collected voluntarily and is used for the benefit of Cardialysis. For example, Cardialysis retains contact information from contracts and contact forms. The personal data that is collected by Cardialysis is used to provide information to its customers and potential customers.
Cardialysis excels in core laboratory techniques, including electrophysiology and clinical events adjudication. It also excels in data management and site management for trials worldwide. It has established collaborative relationships with renowned research organizations worldwide.